30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Multiple Myeloma
Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)…
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Multiple Myeloma
Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Multiple Myeloma
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Overall Survival — 10.0; 10.2 months — p=0.4172
Plasma Cell Leukemia · Plasmacytoma · Recurrent Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) — 38; 24 Participants
Refractory Plasma Cell Myeloma
Primary: Overall Response Rate — 0.35 proportion of participants
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6 Participants
Multiple Myeloma in Relapse · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 53; 14; 35 Participants
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Refractory Multiple Myeloma
Primary: Find Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Pomalidomide and Dexamethasone Out to 2.5 Years, by Count of Patients With Dose Limiting Toxicities…
Multiple Myeloma
Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients
Multiple Myeloma and Plasma Cell Neoplasm
Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change
Multiple Myeloma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants
Relapsed or Refractory Multiple Myeloma
Primary: Maximally Tolerated Dose — 40 mg
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Relapsed and Bortezomib Refractory Multiple Myeloma · Refractory Multiple Myeloma · Multiple Myeloma in Relapse
Primary: Overall Response Rate (PR+nCR+CR) — 34.5 percentage of participants
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Multiple Myeloma
Primary: Number of Participants With VGPR or Better Response to Induction — 6 Participants — p=0.597
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: MTD, Defined as the Highest Dose in Which =< 1/6 Patients Experience a Dose-limiting Toxicity, Graded According to the National Cancer Institute Common Terminology…